Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that Peter Greenleaf, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT in San Francisco, CA. Interested parties can listen to the live audio webcast on the Aurinia corporate website under the 'News/Events' section. Aurinia is dedicated to developing therapies for serious diseases, having launched LUPKYNIS®, the first FDA-approved oral treatment for active lupus nephritis in January 2021.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11^th at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time in San Francisco, CA.

To participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005890/en/

Investor/Media Contact:

Aurinia@westwicke.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

What is the date of Aurinia Pharmaceuticals' presentation at the J.P. Morgan Healthcare Conference?

Aurinia Pharmaceuticals is scheduled to present on January 11 at 4:30 p.m. PT.

Who will be presenting for Aurinia Pharmaceuticals at the conference?

Peter Greenleaf, President and CEO of Aurinia Pharmaceuticals, will be presenting.

Where can I access the webcast for Aurinia Pharmaceuticals' presentation?

The audio webcast can be accessed on Aurinia's corporate website under the 'News/Events' section.

What significant product did Aurinia Pharmaceuticals launch in January 2021?

In January 2021, Aurinia launched LUPKYNIS®, the first FDA-approved oral therapy for active lupus nephritis.

What is the stock symbol for Aurinia Pharmaceuticals?

The stock symbol for Aurinia Pharmaceuticals is AUPH.